Astrazeneca Plc Stock Number Of Shares Shorted
| A1ZN34 Stock | BRL 66.75 1.15 1.75% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca |
AstraZeneca PLC Company Number Of Shares Shorted Analysis
AstraZeneca PLC's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, AstraZeneca PLC has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-General (which currently averages 0.0) industry. The number of shares shorted for all Brazil stocks is 100.0% higher than that of the company.
Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 1.25 T | |||
| Shares Outstanding | 9.3 B | |||
| Price To Book | 3.09 X | |||
| Price To Sales | 25.25 X | |||
| Revenue | 37.42 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 7.54 B | |||
| Net Income | 112 M | |||
| Total Debt | 28.13 B | |||
| Book Value Per Share | 11.96 X | |||
| Cash Flow From Operations | 5.96 B | |||
| Earnings Per Share | 1.85 X | |||
| Price To Earnings To Growth | 0.68 X | |||
| Number Of Employees | 10 | |||
| Beta | 0.19 | |||
| Market Capitalization | 1.13 T | |||
| Total Asset | 105.36 B | |||
| Z Score | 24.0 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 105.36 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.